Pharmacy

Your Article Summary

See Latest Articles

A phase I/II trial of fixed-dose docetaxel plus irinotecan and escalating doses of estramustine phosphate for second-line or greater treatment of selected advanced solid tumors
Anti-Cancer Drugs, 07/02/09

Baz W et al. - In a study to evaluate the safety and efficacy of combination irinotecan, docetaxel, and estramustine for selected advanced solid tumors, it was concluded that estramustine in combination with docetaxel and irinotecan is a well-tolerated regimen with minimal hematologic toxicity, mild to moderate nonhematologic toxicity, and promising initial antitumor activity in previously treated pts with advanced solid tumors.

• 22 pts were enrolled.
• The regimen consisted of docetaxel 30 mg/m2 and irinotecan 60 mg/m2 both given intravenously on days 1 and 8 every 21 days in combination with escalating doses of estramustine (500 mg/m2/day escalated to 750 mg/m2/day on days 0, 1, 2, 7, 8, and 9 given every 21 days) during phase I.
• Dose escalation was continued until maximum planned dose level of estramustine (750 mg/m2/day) was reached.
• After the appropriate phase II dose of estramustine was found, additional pts were enrolled.

• 21 of 22 pts were evaluable for toxicity and 17 for tumor response.
• Recommended phase II dose of estramustine was 750 mg/m2/day orally on days 0, 1, 2, 7, 8, and 9 given every 21 days.
• Hematologic toxicity was fairly mild, with only 1 episode of grade 3 neutropenia.
• Diarrhea was the most common nonhematologic toxicity with grade 3 toxicity occurring in 5 of 21 pts.
• Only 1 episode of venous thrombosis was observed.
• Objective response rate was 15.8%, overall clinical benefit rate was 63%, and median time to progression was 15 wks.

Related Articles

See all related articles

Electrocardiographic Characterization of the QTc Interval in Patients with Advanced Solid Tumors: Pharmacokinetic- Pharmacodynamic Evaluation of Sunitinib
Clinical Cancer Research, 11/16/09    Relevance Score: 80%

A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors
Cancer Chemotherapy and Pharmacology, 10/01/09    Relevance Score: 80%

Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors
Clinical Cancer Research, 10/01/09    Relevance Score: 80%

Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: Results from a phase II randomized, factorial, double-blind study of cediranib in patients with advanced solid tumors
Journal of Clinical Oncology, 11/13/09    Relevance Score: 79%

A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors
Clinical Cancer Research, 10/15/09    Relevance Score: 79%

Today in Chemotherapy/Oncology...keeping you current

Receive free subspecialty "5-minute updates" via email

Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 2010
Cell Therapeutics, 12/18/09

Oral Chemotherapy in Hormone-Refractory Prostate Carcinoma Patients Unwilling to Be Admitted to Hospital
Urologia Internationalis, 12/18/09

Taurolidine in the prevention and therapy of lung metastases
European Journal of Cardio-Thoracic Surgery, 12/17/09

 See all of Chemotherapy/Oncology

Today in Dosing...keeping you current

Receive free subspecialty "5-minute updates" via email

Low levels of steroid-metabolizing hepatic enzyme activity may elevate responsiveness to steroids and may increase risk of steroid-induced osteonecrosis even with low glucocorticoid dose
Journal of Orthopaedic Science, 12/18/09

Optimizing Epidural Fentanyl Loading Dose for Early Labor Pain
Acta Anaesthesiologica Taiwanica, 12/17/09

Efficacy and safety of a single intrathecal methylprednisolone bolus in chronic complex regional pain syndrome
European Journal of Pain, 12/17/09

 See all of Dosing

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
ARIAD Pharmaceuticals, 12/18/09

Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
Investigational New Drugs, 12/17/09

Milatuzumab – a promising new immunotherapeutic agent
Expert Opinion on Investigational Drugs, 12/17/09

 See all of Drug Trials